|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-9-1
|
|
pubmed:abstractText |
One of the problems possibly related to the use of biological agents targeting tumor necrosis factor (TNF)-alpha is the increased risk of infections, including the activation of hepatitis B virus (HBV). HBV activation can occur in carriers of hepatitis B surface antigen (HBsAg), but the risk may also involve the HBsAg-negative (anti-HBc ± anti-HBs) occult carriers. Precise data on the safety of anti-TNF and/or other immunosuppressive drugs in HBV occult carriers are not available. We performed a retrospective analysis of 62 psoriatic patients with occult HBV infection treated with anti-TNF biological agents over a period of approximately 4 years: 44 subjects were treated with etanercept, 8 with infliximab and 10 with adalimumab. During the observational treatment period, no signs of HBV activation were observed. Only in one patient the reappearance of HBsAg, without detectable HBV-DNA, was noted before retreatment with etanercept and after 10 months from discontinuation of the previous course. In this patient etanercept was re-administered in association with lamivudine without any adverse event. Our results suggest the overall safety of treatment with anti-TNF drugs in HBV occult carriers, although a careful and constant monitoring of virological markers is required in such patients during treatment with anti-TNF drugs in order to have an early recognition of viral reactivation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Surface Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Reverse Transcriptase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/adalimumab,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0393-974X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
285-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21880218-Adult,
pubmed-meshheading:21880218-Aged,
pubmed-meshheading:21880218-Anti-Inflammatory Agents,
pubmed-meshheading:21880218-Antibodies,
pubmed-meshheading:21880218-Antibodies, Monoclonal,
pubmed-meshheading:21880218-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21880218-Carrier State,
pubmed-meshheading:21880218-Drug Combinations,
pubmed-meshheading:21880218-Female,
pubmed-meshheading:21880218-Hepatitis B,
pubmed-meshheading:21880218-Hepatitis B Surface Antigens,
pubmed-meshheading:21880218-Hepatitis B virus,
pubmed-meshheading:21880218-Humans,
pubmed-meshheading:21880218-Immunoglobulin G,
pubmed-meshheading:21880218-Lamivudine,
pubmed-meshheading:21880218-Male,
pubmed-meshheading:21880218-Middle Aged,
pubmed-meshheading:21880218-Psoriasis,
pubmed-meshheading:21880218-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:21880218-Retrospective Studies,
pubmed-meshheading:21880218-Reverse Transcriptase Inhibitors,
pubmed-meshheading:21880218-Tumor Necrosis Factor-alpha,
pubmed-meshheading:21880218-Virus Latency
|
|
pubmed:articleTitle |
Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.
|
|
pubmed:publicationType |
Letter
|
